Cognitive functioning in schizophrenia. Effects of drug treatments

CNS Drugs

Volumn 6, Issue 5, 1996, Pages 382-398

  Green, Jonathan F ^a   King, David J ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b Holywell Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; BENZODIAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; PERPHENAZINE; REMOXIPRIDE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

COGNITION; COGNITIVE DEFECT; DRUG THERAPY; HUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 0029908766     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199606050-00005     Document Type: Review

References (79)

1. King DJ. The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry 1990; 157: 799-811
2. Tecce JJ, Cole JO. Psychophysiologic responses of schizophrenics to drugs. Psychopharmacologia 1972; 24: 159-200
3. Healy D. Neuroleptics and psychic indifference: a review. J R Soc Med 1989; 82: 615-9
4. Hemsley DR. A two-stage model of attention in schizophrenia research. Br J Soc Clin Psychol 1975; 14: 81-9
5. Joseph MH, Frith CD, Waddington JL. Dopaminergic mechanisms and cognitive deficit in schizophrenia. Psychopharmacology 1979; 63: 273-80
6. Berger HJC, van Hoof JJM, van Spaendonck KPM, et al. Haloperidol and cognitive shifting. Neuropsychologia 1989; 27: 629-19
7. Clark CR, Geffen GM, Geffen LB. Catecholamines and the covert orientation of attention in humans. Neuropsychologia 1989; 27: 131-9
8. King DJ. Measures of neuroleptic effects on cognition and psychomotor performance in healthy volunteers. In: Hindmarch I, Stonier PD, editors. Human psychopharmacology: measures and methods. Vol. 4. Chichester: John Wiley & Sons Ltd, 1993: 195-209
9. Heaton RK, Crowley TJ. Effects of psychiatric disorders and their somatic treatments on neuropsychological test results. In: Filskov SB, Boll TJ, editors. Handbook of clinical neuropsychology. Chichester: John Wiley & Sons Ltd, 1981: 481-525
10. Medalia A, Gold J, Merriam A. The effect of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 1988; 3: 249-71
11. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnormal Psychol 1989; 98: 367-80
12. Cassens G, Inglis AK, Appelbaum PS, et al. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990; 16: 477-99
13. McKenna PJ, Tamlyn D, Lund CE, et al. Amnesic syndrome in schizophrenia. Psychol Med 1990; 20: 967-72
14. Tamlyn D, McKenna PJ, Mortimer AM, et al. Memory impairment in schizophrenia: its extent, affiliations and neuropsychological character. Psychol Med 1992; 22: 101-15
15. Fink M. EEG and human psychopharmacology. Annu Rev Pharmacol 1969; 9: 241-58
16. Saletu B, Küfferle B, Grünberger J, et al. Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy. Pharmacopsychiatry 1986; 19: 434-7
17. Saletu B, Grünberger J, Linzmayer L, et al. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilising pharmaco-EEG and psychometry Pharmacopsychiatry 1987; 20: 12-27
18. Merrin EL, Floyd TC, Fein G. Task-related EEG alpha asymmetry in schizophrenic patients prior to and after neuroleptic treatment. Schizophr Res 1988; 1: 283-93
19. Bartel P, Blom M, van der Meyden C, et al. Effects of single-doses of diazepam, chlorpromazine, imipramine and trihexyphenidyl on visual-evoked potentials. Neuropsychobiology 1988; 20: 212-7
20. Kemali D, Galderisi S, Maj M, et al. Lateralization patterns of event-related potential and performance indices in schizophrenia: relationship to clinical state and neuroleptic treatment. Int J Psychophysiol 1991; 10: 225-30
21. Nakagawa M, Takeda K, Kakimoto Y. Characteristic distribution of alpha 2 wave in electroencephalograms of schizophrenic patients during discriminative tasks: support for the hypofrontality hypothesis of schizophrenia. Acta Psychiatr Scand 1991; 83: 105-14
22. Roth WT, Goodale J, Pfefferbaum A. Auditory event-related potentials and electrodermal activity in medicated and unmedicated schizophrenics. Biol Psychiatry 1991; 29: 585-99
23. Liddle PF, Friston KJ, Frith CD, et al. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992; 160: 174-86
24. Kornetsky C, Pettit M, Wynne R, et al. A comparison of the psychological effects of acute and chronic administration of chlorpromazine and secobarbital (quinalbarbitone) in schizophrenic patients. J Med Sci 1959; 105: 190-8
25. Latz A, Kornetsky C. The effects of chlorpromazine and secobarbital under two conditions of reinforcement on the performance of chronic schizophrenic subjects. Psychopharmacologia 1965; 7: 77-88
26. Rosvold HE, Mirsky AF, Sarason I, et al. A continuous performance test of brain damage. J Consult Psychol 1956; 20: 343-50
27. Wahba M, Donlon PT, Meadow A. Cognitive changes in acute schizophrenia with brief neuroleptic treatment. Am J Psychiatry 1981; 138: 1307-10
28. Braff DL, Saccuzzo DP. Effect of antipsychotic medication on speed of information processing in schizophrenic patients. Am J Psychiatry 1982; 139: 1127-30
29. Walker E. Attentional and neuromotor functions of schizophrenics, schizoaffectives, and patients with other affective disorders. Arch Gen Psychiatry 1981; 38: 1355-8
30. Walker E. Cognitive changes in schizoaffective patients. Arch Gen Psychiatry 1983; 40: 1255
31. Erickson WD, Yellin AM, Hopwood JH, et al. The effects of neuroleptics on attention in adolescent schizophrenics. Biol Psychiatry 1984; 19: 745-53
32. Killian GA, Holzman PS, Davis JM, et al. Effects of psychotropic medication on selected cognitive and perceptual measures. J Abnormal Psychol 1984; 93: 58-70
33. Marder SR, Asarnow RF, van Putten T. Information processing and neuroleptic response in acute and stabilized schizophrenic patients. Psychiatry Res 1984; 13: 41-9
34. Spohn HE, Coyne L, Lacoursiere R, et al. Relation of neuroleptic dose and tardive dyskinesia to attention, information-processing and psychophysiology in medicated schizophrenics. Arch Gen Psychiatry 1985; 42: 849-59
35. Spohn HE, Coyne L, Mittleman F, et al. Effect of neuroleptic treatments on attention, information processing, and thought disorder. Psychopharmacol Bull 1985; 21: 582-7
36. Strauss ME, Lew MF, Coyle JT, et al. Psychopharmacologic and clinical correlates of attention in chronic schizophrenia. Am J Psychiatry 1985; 142: 497-9
37. Berman KF, Zee RF, Weinberger DR. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: II. Role of neuroleptic treatment, attention, and mental effort. Arch Gen Psychiatry 1986; 43: 126-35
38. Fields RB, van Kammen DP, Peters JL, et al. Clonidine improves memory function in schizophrenia independent from change in psychosis. Schizophr Res 1988; 1: 417-23
39. Bartkó G, Frecska E, Zador G, et al. Neurological features, cognitive impairment and neuroleptic response in schizophrenic patients. Schizophr Res 1989; 2: 311-3
40. Calvert JE, Bahiker IE, Harris JP, et al. Object-name selection in psychiatric patients before and after neuroleptic therapy. J Psychopharmacol 1990; 4: 75-82
41. Cleghorn JM, Kaplan RD, Szechtman B, et al. Neuroleptic drug effects on cognitive function in schizophrenia. Schizophr Res 1990; 3: 211-9
42. Cutmore TRH, Beninger RJ. Do neuroleptics impair learning in schizophrenic patients? Schizophr Res 1990; 3: 173-86
43. Gold JM, Hurt SW. The effects of haloperidol on thought disorder and IQ in schizophrenia. J Personality Assess 1990; 54: 390-400
44. Harvey PD, Keefe RSE, Moskowitz J, et al. Attentional markers of vulnerability to schizophrenia: performance of medicated and unmedicated patients and normals. Psychiatry Res 1990; 33: 179-88
45. Serper MR, Bergman RL, Harvey PD. Medication may be required for the development of automatic information processing in schizophrenia. Psychiatry Res 1990; 32: 281-8
46. Harle-Boyer EA, Serper MR, Davidson M, et al. Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance. Psychiatry Res 1991; 37: 47-56
47. Goldberg TE, Bigelow LB, Weinberger DR, et al. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry 1991; 148: 78-84
48. Nestor PG, Faux SF, McCarley RW, et al. Neuroleptics improve sustained attention in schizophrenia: a study using signal detection theory. Neuropsychopharmacology 1991; 4: 145-9
49. Seidman LJ, Pepple JR, Faraone SV, et al. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biol Psychiatry 1993; 33: 575-84
50. Classen W, Laux G. Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine. Pharmacopsychiatry 1988; 21: 295-7
51. Classen W, Laux G. Comparison of sensorimotor and cognitive performance of acute schizophrenic inpatients treated with remoxipride or haloperidol. Neuropsychobiology 1989; 21: 131-40
52. Strauss WH, Klieser E. Cognitive disturbances in neuroleptic therapy. Acta Psychiatr Scand 1990; 82 Suppl. 358: 56-7
53. Goldberg TE, Greenberg RD, Griffin SJ, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993; 162: 43-8
54. Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993; 34: 702-12
55. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994; 36: 717-25
56. Zahn TP, Pickar D, Haier RJ. Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophr Res 1994; 13: 133-44
57. Spohn HE, Lacoursiere RB, Thompson K, et al. Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics. Arch Gen Psychiatry 1977; 34: 633-44
58. Oades RD. Attention and schizophrenia: neurobiological bases. London: Pitman Books Limited, 1982: 30-6
59. Posner MI, Walker JA, Friedrich FA, et al. How do the parietal lobes direct covert attention? Neuropsychologia 1987; 25: 135-45
60. Posner MI, Petersen SE, Fox PT, et al. Localization of cognitive operations in the human brain. Science 1988; 240: 1627-31
61. Posner MI, Petersen SE. The attention system of the human brain. Annu Rev Neurosci 1990; 13: 25-42
62. Oades RD. Attention and schizophrenia: neurobiological bases. London: Pitman Books Limited, 1982: 159-72
63. Waddington JL. Tardive dyskinesia in schizophrenia and other disorders: associations with ageing, cognitive dysfunction and structural brain pathology in relation to neuroleptic exposure. Hum Psychopharmacol 1987; 2: 11-22
64. Collerton D, Fairbairn A, Britton P. Cognitive performance of medicated schizophrenics with tardive dyskinesia. Psychol Med 1985; 15: 311-5
65. Myslobodsky MS, Tomer R, Holden T, et al. Cognitive impairment in patients with tardive dyskinesia. J Nerv Ment Dis 1985; 173: 156-60
66. Marsalek M, Pavlat DJ, Petrovsky M, et al. The signs of brain vulnerability in tardive dyskinesia. Schizophr Res 1988; 1: 231
67. Soni SD, Neill D, Sheffield B. Cognitive functions in chronic schizophrenic patients with tardive dyskinesia. Hum Psychopharmacol 1993; 8: 233-42
68. Barnes TRE, Crichton P, Nelson HE, et al. Primitive developmental reflexes, tardive dyskinesia and intellectual impairment in schizophrenia. Schizophr Res 1995; 16: 47-52
69. Waddington JL, O'Callaghan E, Buckley P, et al. Tardive dyskinesia in schizophrenia - relationship to minor physical anomalies, frontal lobe dysfunction and cerebral structure on magnetic resonance imaging. Br J Psychiatry 1995; 167: 41-4
70. Crow TJ. Molecular pathology of schizophrenia: more than one disease process? BMJ 1980; 280: 66-8
71. Gruzelier JH, Seymour K, Wilson L, et al. Impairments on neuropsychologic tests of temporohippocampal and frontohippocampal function and word fluency in remitting schizophrenia and affective disorders. Arch Gen Psychiatry 1988; 45: 623-9
72. Tomer R, Mintz M, Myslobodsky MS. Left hemisphere hyperactivity in schizophrenia: abnormality inherent to psychosis or neuroleptic side-effects? Psychopharmacology 1982; 77: 168-70
73. Tomer R, Flor-Henry P. Neuroleptics reverse attention asymmetries in schizophrenic patients. Biol Psychiatry 1989; 25: 852-60
74. Tomer R. Neuroleptic effects on interhemispheric and intrahemispheric performance of tactile discrimination tasks by schizophrenic patients. Psychiatry Res 1990; 32: 289-96
75. Frazier MF, Silverstein ML, Fogg L, Lateralized cerebral dysfunction in schizophrenia and depression: gender and medication effects. Arch Clin Neuropsychol 1989; 4: 33-44
76. Seidman LJ. Schizophrenia and brain dysfunction: an integration of recent neuro-diagnostic findings. Psychol Bull 1983; 94: 195-238
77. Tune LE, Strauss ME, Lew MF, et al. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 1982; 139: 1460-2
78. Katz IR, Greenberg WH, Barr GA, et al. Screening for cognitive toxicity of anticholinergic drugs. J Clin Psychiatry 1985; 46: 323-6
79. Perlick D, Stastny P, Katz I, et al. Memory deficits and anticholinergic levels in chronic schizophrenia. Am J Psychiatry 1986; 143: 230-2